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ABSTRACT 
Introduction: Parkinson`s disease (PD) is the second most common neurodegenerative condition affecting 
patients. It is broadly classified as `movement disorder’ with a variety of clinical features, including bradykinesia, 
rigidity and tremor. PD is better defined as multisystem neurodengerative disorder causing a large number of 
motor and non-motor complications. In this study we described our experience regarding follow up parkinsonism 
patients. 
Objectives:  To determine clinical outcome in patients of Parkinsonism in our setup. 
Materials and Methods:  This was a retrospective as well as follow up of new patients of Parkinson`s disease in 
the department of neurology at Royal Commission hospital Yanbu – one of the biggest industrial city of Kingdom 
of Saudi Arabia. Duration of study was two years; from January 2011 to December 2012. This study included 50 
patients with diagnosed case of Parkinsonism and newly diagnosed cases. 
Results:  The age range was 40 – 110 years; there were 4 patients (8%) of age range 40 – 41 years, 2 patients 
(4%) of age range 46 – 50 years, one patient (2%), 7 patients (14%) of age range 61 – 65 years, 11 patients 
(22%) of age range 66 – 70 years, 2 patients (4%) of age range 86 – 90 years and one patient (2%) was of 110 
years. The last patient mentioned has a daughter who was 80 years of age and was included in the study. Around 
45 patients were diagnosed for the first time as case of Parkinsonism and these were started on management / 
treatment with good clinical improvement. 
Conclusions:  Not all the patients need to commence treatment at time of diagnosis, but drugs should be started 
when symptoms begin to interfere with daily life. We found that all such patients when prescribed treatments sho-
wed excellent improvement in terms of activities of daily life. 
Key Words:  Parkinsonism, idiopathic parkinsonism, Parkinson`s disease (PD) 
Abbreviations:  PD = Parkinson`s disease. 
 
INTRODUCTION 
Parkinsonism is a syndrome characterized by the triad 
of tremor, rigidity, postural instability and bradyki-
nesia. In terms of management, patient, patients can be 
divided into toe groups: those with Parkinson‘s disease 
(who respond well to levodopa) and those atypical 
Parkinsonism (who do not). In atypical parkinsonian 
syndromes, there is loss of striatal neurons in addition 
to nigral neurons. The relative involvement of each 
region in individual patients and diseases determines
 
the degree of dopa responsiveness. The study was car-
ried to see 50 patients of Parkinsonism. 
 The study was conducted at neurology department 
Royal Commission hospital Yanbu, Kingdom of Saudi 
Arabia from the year 2010 to 2012. This hospital is a 
tertiary care hospital that has a well established depart-
ment of neurology. The aim of the study was to see 
symptomology of the disease, its progression and use 
of medications for the disease. The diagnosis was 
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based on history, clinical examination, imaging and 
family history of the disease. 
 
OBJECTIVE 
The objective of the study was to see the clinical pre-
sentation, family history, treatment and outcome of 
management of patients of Parkinsonism following in 
the neurology OPD of the Royal commission hospital. 
We re-evaluated these patients and included the new 
patients in the study. 
 
MATERIAL AND METHODS 
Study Design 
Retrospective and prospective study. 
 
Duration of Study 
From 1
st
 of January 2010 to 31
st
 of December 2012. 
 
Setting 
Department of neurology Royal Commission hospital 
Yanbu, Kingdom of Saudi Arabia. 
 
Sample Size 
We collected 50 patients; 5 patients were already fol-
lowing in the neurology OPD and 45 patients were 




 Patients of both sexes were selected. 
 All young and old patients were selected from age 
40 years onward. 
 
Exclusion Criteria 
 Patients of cerebral tumors and parkinsonism Plus 
were excluded from the study. 
 Patients who had parkinsonism secondary to the 




Fifty patients fulfilling the inclusion criteria were en-
rolled through OPD department of neurology, Royal 
commission hospital Yanbu, KSA. An informed con-
sent was obtained before imaging. The demographic 
information like name, age, sex, and address were 
recorded. No ethical issues were involved. 
 
Table 1:  Age Range. 
 
Age Range (Years) No. of Patients 
40 – 41   4 
46 – 50   2 
56 – 60   1 
61 – 65   7 
66 – 70 11 
71 – 75 10 
56 – 60   6 
81 – 85 - 
86 – 90   2 
> 90      1 
 
 As we shall see that we found lots of families with 
Parkinsonism; we had eight patients with strong family 
history of Parkinsonism. Out of these in one family 
there were three brothers and all of these had Parkin-
sonism. Most of these family members were included 
in the study and all of these were called in neurology 
OPD for management. The following table shows both 
groups showing number patients in either group. 
 
Table 2:  Family History. 
 
1. No family history of Parkinsonism 33 
2. 




 The patients were prescribed all groups of medi-
cines with variable response. These are shown in the 
following table: 
 The following medications were used for the treat-
ment of patients: 
1. Sinemet (levodopa 250 / carbidopa 25). 
2. Anticholinergics: Artan/ Hexidil (trihexyphenidyl) 
and Kemadrin (procyclidine). 
3. Dopamine agonists: amantidine. 
4. Surgical referral. 
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Table 3:  Treatment Given. 
 
1. Dopamine (levodopa / carbidopa) 26 
2. Dopamine agonists 6 
3. Anticholinergics 37 
4. No treatment 7 
 
 While carrying out this study we carried out brain 
imaging in all patients, we tried to carry out brain ima-
ging in all patients. This is shown in following table: 
 
Table 4:  No. of Patients with Cerebral Imaging. 
 
1. Normal CT or MRI 33 
2. Abnormal CT / MRI 12 
3. No imaging done   5 
 
Table 5:   
 
Total number of patients 50 
Male patients 34 
Female patients 16 
 
Table 6:  Parkinsonism diagnostic criteria. 
 
1. Normal CT or MRI 
2. Bradykinesia 
3. Rigidity 
4. Loss of postural reflexes 
5. Flexed posture 
6. Freezing (motor blocks) 
Definite: at least two of these features must be present, 
one of them being 1 or 2 
Probable: feature 1 or 2 alone is present 
Possible: at least two of features 3 to 6 must be present 
 
DISCUSSION 
Parkinsonism is syndrome manifested by a combinat-
ion of the following six cardinal features: 
Tremor – at rest, rigidity, bradykinesia, loss of postural 
reflexes, flexed posture. Freezing (motor block). 
 A combination of these signs is used clinically 
define definite, probable, and possible Parkinsonism 
(table 6). 
 Parkinson‘s disease affects over 1% of all people 
over 50 years of age. 
 5 – 10% of the patients with Parkinson`s disease 
present at age less 40 years of age. 
 There is a similar incidence in males and females. 
 All ethnic groups are equally affected. 
 The diagnosis is clinical. Investigations are requi-
red only if there is doubt about the diagnosis. MRI is 
more sensitive than CT scan, for example detecting 
infarcts or focal gliosis or atrophy (as occurs, for exa-
mple, in the putamen in multiple system atrophy). 
 The way that patient are given their diagnosis can 
have a lasting influence on their attitude to their illness 
and subsequent quality of life. It is useful to point out 
that: 
 Parkinson‘s disease progresses slowly over many 
years, in younger patients over decade. 
 Although there is no cure, there is very effective 
and long – lasting treatment to control the symp-
toms. 
 Because the disease advances slowly, there will be 
time to make any necessary adjustments to the ill-
ness. 
 Progression is very variable, and many patients 
retain normal or near-normal functions for many 
year. 
 Younger patients often have great difficulty in 
coming to terms with the diagnosis; there is little point 
in prescribing drugs until the patient have accepted the 
diagnosis and wants treatment. 
 The aim of initial treatment is to reduce motor 
disability while minimizing the risk of medium – to 
long – term complications of therapy. No treatment 
has been shown to slow disease progression. Conver-
sely, no drug (including levodopa) has been shown 
worsen disease progression. This is important to em-
phasize because many patients have concerned about 
potential drug toxicity based on theoretical and labora-
tory data obtained from the internet and other sources. 
Management can be divided into three stages; 
 Early stage of good symptom control. 
 Mid – stage, when the ‗honeymoon‘ ends and pro-
blems such as motor fluctuations and dyskinesias 
appear. 
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 Late – stage, when problems resistant to levodopa 
such as falls and dementia emerge. 
 In our study we have a total of 50 patients and 
these patients followed in neurology department at 
Royal commission hospital Yanbu from January 2012 
to December 2012. The age range is 40 – 91 years. Out 
of these 34 are males and 16 are females. Among these 
patients, 17 had family history of Parkinsonism and 33 
patients did not have family history of the disease. All 
the patients have rest tremors (from very minor to gro-
ss shaking of hands) and bradykinesia. The occurrence 
of postural instability and other features was variable. 
All of these patients had imaging; CT / MRI was nor-
mal in 33 patients and it was abnormal in 17 – the 
abnormalities being multiple infarcts and cerebral 
atrophy. Out of 50 patients, 26 were prescribed levo-
dopa, 6 were taking anticholinergics and 7 patients did 
not have treatment (these were not started any treat-
ment or they did not accept treatment). Many patients 
who did not receive treatment prior to presentation 
were started on either of three groups of medicines 
(anticholingergics, dopamine agonists, and levodopa). 
These patients showed good improvement following 
treatment. 




We found that all of the patients who were started on 
drugs for Parkinson`s disease started improving in 
terms of daily life and care giving. Those who were al-
ready diagnosed, they got their medications adjusted 
as well and started improving – both subjective and 
objective. 
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